SCHEMBL24671506

SCHEMBL24671506

CC(C)(C)OC(=O)N1CCC(CN2CCN(c3cc(-c4ccc(OCc5ccccc5)nc4OCc4ccccc4)ccn3)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.43
YAP1 P46937 3/20 0.42
PRMT5 O14744 4/20 0.41
ACHE P22303 1/20 0.41
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
CCNT1 O60563 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CDK9 P50750 1/20 0.40
CCNA1 P78396 1/20 0.40
USP30 Q70CQ3 1/20 0.40
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
ALK Q9UM73 1/20 0.39
TLR9 Q9NR96 1/20 0.39
TLR7 Q9NYK1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30066316 1.00 GPR119 (0.43) GPR119YAP1PRMT5ACHECKS1B
SCHEMBL31342391 0.89 YAP1 (0.44) GPR119YAP1PRMT5ALK
SCHEMBL31342432 0.89 YAP1 (0.44) GPR119YAP1PRMT5ALK
SCHEMBL29990523 0.88 GPR119 (0.47) GPR119YAP1PRMT5ACHEALK
SCHEMBL24670554 0.88 GPR119 (0.47) GPR119YAP1PRMT5ACHEALK
SCHEMBL30066495 0.88 P2RY12 (0.41)
SCHEMBL30801241 0.86 GPR119 (0.45) GPR119YAP1PRMT5CKS1BSKP1
SCHEMBL24670651 0.86 GPR119 (0.45) GPR119YAP1PRMT5CKS1BSKP1
SCHEMBL30981436 0.86 VCP (0.46) GPR119YAP1PRMT5CCNT1CCNA2
SCHEMBL24670637 0.85 GPR119 (0.47) GPR119YAP1PRMT5ACHECCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279202-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. 2024-08-22 US disclosed
WO-2022235715-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279202-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE ITK, NFATC1, TNIK GPR119 3873/4885YAP1 3073/4885PRMT5 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.